Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin plus Anti-PD-1 Antibody in Metastatic TNBC
NCT05402722Phase 2Unknown
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, eribulin in triple-negative breast cancer (TNBC), sponsored by The Fifth Medical Center of the PLA General Hospital. Status: unknown.
02
Drugs
sintilimaberibulin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05402722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05402722.